Plasma levels of CST are reduced in patients suffering from T2DM and hypertension (75, 95, 98), whereas elevated levels of the pro-hormone CgA have been detected in the plasma of patients with neuroendocrine tumors (25), hypertension (99, 100) and various inflammatory diseases, such as RA (6, 101, 102), SLE (6), inflammatory bowel disease (IBD) (53, 54, 103–105) as well as T1DM and T2DM (62, 106–109). This evidence concerns the gene CGA and type 1 diabetes mellitus.